权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

EAGER: Quantifying SARS-CoV-2 antigen-antibody binding using cell-free guide RNA display

EAGER：使用无细胞引导 RNA 展示定量 SARS-CoV-2 抗原抗体结合

基本信息

批准号：
2032794
负责人：
James Carothers
金额：
$ 30万
依托单位：
University of Washington
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-15 至 2021-12-31
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=2032794&HistoricalAwards=false
关键词：
EAGER Quantifying SARS CoV antigen

项目摘要

The lack of reliable and widely-available SARS-CoV-2 antibody testing has left many unanswered questions. For example, although it is known that SARS-CoV-2 specific antibodies appear within two weeks of someone becoming infected with the virus. However several factors are unknown, including a) the viral loads that generate antibody responses; b) how long SARS-CoV-2 antibodies last; or c) the amount of antibody needed for protection. The creation of low-cost, high-accuracy platforms for SARS-CoV-2 antibody analysis could therefore play a crucial role in tracking the spread of COVID-19, informing epidemiological responses, and supporting the development of diagnostics, treatments, and vaccines. This project will develop a low-cost alternative for rapidly measuring SARS-CoV-2 antibody binding. These systems could be used to measure SARS-CoV-2 antibody titers in patient samples and allow researchers to better model the spread and understand the disease course of COVID-19. The development of this customizable antibody detection platform will also make it easier to respond to future novel pandemics. In addition, the platform has substantial potential as a general research tool, as it could be used to detect a variety of antigen-antibody interactions. Broader impacts: The proposed system will provide a scalable, low-cost alternative to the ELISA that could be used to measure SARS-CoV-2-specific antibody titers in patient samples and facilitate efforts to model the spread and understand the etiology of COVID-19. Immediate broader impacts of the project also include i) unique opportunities for Ph.D. and undergraduate students to participate in use-inspired science and engineering, ii) engagement with diverse public audiences to communicate key ideas about the science of COVID-19 antibody testing, and iii) graphic materials about the science of COVID-19 antibody testing for use in public-facing events and sharing via social media that will be freely available under Creative Commons licenses.This project will develop a cell-free transcription and translation (TXTL) platform for measuring SARS-CoV-2 antigen-antibody binding with the quantitative precision of ELISA, and the easy customizability and scalability of a system that is entirely genetically-encoded. Recent work developed a programmable CRISPR-Cas transcriptional activation (CRISPRa) system for E. coli and TXTL that uses modified guide RNAs (gRNAs) to recruit a transcriptional activator. Here, the goal is to engineer CRISPRa as a platform for quantifying antigen-antibody binding by making CRISPRa activity conditional to the presence of IgG antibodies in a sample. It is straightforward to couple CRISPRa activity to visible outputs, and the system developed here could provide a scalable, low-cost alternative to ELISAs that permits the quantification of antibody titers using only DNA and TXTL master mix as reagents. Even more, because of the inherent multiplexing capabilities of CRISPRa, it will be possible to develop new diagnostics that produce a signal only upon detection of multiple antigens, resulting in lower false-positive rates. Intellectual merit: Developing scalable approaches to rapidly quantify antigen-antibody binding is a long-standing scientific and engineering challenge. By developing rules to couple antigen-antibody binding to CRISPRa-directed reporter gene expression, this project will create assays for measuring SARS-CoV-2 antigen-antibody binding using DNA-programmed cell-free platforms that are easy to customize and could be readily re-configured as point-of-care diagnostics. While there are a number of CRISPR-based tools that are being adapted to detect viral nucleic acids, the proposed system is comparatively unique as a sensor for protein antibody detection. This EAGER award is made by the Systems and Synthetic Biology Program in the Division of Molecular and Cellular Biosciences, using funds from the Coronavirus Aid, Relief, and Economic Security (CARES) Act.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

由于缺乏可靠和广泛可用的SARS-CoV-2抗体检测，留下了许多悬而未决的问题。例如，尽管已知SARS-CoV-2特异性抗体在某人感染病毒后两周内出现。然而，有几个因素是未知的，包括a）产生抗体反应的病毒载量; B）SARS-CoV-2抗体持续多久;或c）保护所需的抗体量。因此，建立低成本、高准确度的SARS-CoV-2抗体分析平台可以在跟踪COVID-19传播、为流行病学应对提供信息以及支持诊断、治疗和疫苗开发方面发挥关键作用。该项目将开发一种快速测量SARS-CoV-2抗体结合的低成本替代方法。这些系统可用于测量患者样本中的SARS-CoV-2抗体滴度，并使研究人员能够更好地模拟COVID-19的传播并了解其病程。这种可定制的抗体检测平台的开发也将使其更容易应对未来的新型流行病。此外，该平台具有作为一般研究工具的巨大潜力，因为它可以用于检测各种抗原-抗体相互作用。更广泛的影响：拟议的系统将提供一种可扩展的，低成本的ELISA替代品，可用于测量患者样本中的SARS-CoV-2特异性抗体滴度，并促进对COVID-19传播建模和了解病原学的努力。该项目的直接更广泛的影响还包括i）博士学位的独特机会。和本科生参与使用启发的科学和工程，ii）与不同的公众受众接触，交流有关COVID-19抗体检测科学的关键思想，以及iii）有关COVID-19抗体检测科学的图形材料，用于面向公众的活动，并通过社交媒体分享，这些材料将在知识共享许可下免费提供。该项目将开发一个细胞-免费转录和翻译（TXTL）平台，用于测量SARS-CoV-2抗原抗体结合与ELISA的定量精度，以及完全基因编码的系统的易于定制性和可扩展性。最近的工作开发了一个可编程的CRISPR-Cas转录激活（CRISPRa）系统，用于E。coli和TXTL，其使用经修饰的引导RNA（gRNA）来募集转录激活因子。在这里，目标是通过使CRISPRa活性以样品中IgG抗体的存在为条件来工程化CRISPRa作为用于定量抗原-抗体结合的平台。将CRISPRa活性与可见输出结合是简单的，并且这里开发的系统可以提供ELISA的可扩展的低成本替代方案，其允许仅使用DNA和TXTL主混合物作为试剂来定量抗体滴度。更重要的是，由于CRISPRa固有的多重功能，有可能开发出新的诊断方法，仅在检测到多种抗原时才产生信号，从而降低假阳性率。智力优点：开发可扩展的方法来快速定量抗原-抗体结合是一项长期存在的科学和工程挑战。通过开发将抗原-抗体结合与CRISPRa指导的报告基因表达偶联的规则，该项目将创建使用DNA编程的无细胞平台测量SARS-CoV-2抗原-抗体结合的测定方法，这些平台易于定制，并且可以容易地重新配置为床旁诊断。虽然有许多基于CRISPR的工具适用于检测病毒核酸，但所提出的系统作为蛋白质抗体检测的传感器相对独特。EAGER奖由分子和细胞生物科学部的系统和合成生物学计划颁发，使用冠状病毒援助，救济和经济安全（CARES）法案的资金。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。